Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Breast Cancer, Stage 0 Breast Cancer, St...
Phase PHASE4
Enrollment 60
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to find out whether Revaree Plus is effective at improving vaginal health for people who are having symptoms of vaginal dryness during breast cancer treatment.

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Revaree Plus — Revaree Plus is a hyaluronic acid vaginal suppository

Primary Outcomes

  • Change in Vaginal Assessment Scale from baseline to 8 weeks (8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-06-20
Completion: 2029-06-20
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Principal Investigators:
  • Shari Goldfarb, MD (PRINCIPAL_INVESTIGATOR) - Memorial Sloan Kettering Cancer Center
Contact Information
Study Contact:
Shari Goldfarb, MD
646-888-5080
goldfars@mskcc.org
Jeanne Carter, PhD
646-888-5076
carterj@mskcc.org
Shari Goldfarb, MD
646-888-5080
Memorial Sloan Kettering Basking Ridge (Consent Only)
Interventions
  • Drug: Revaree Plus — Revaree Plus is a hyaluronic acid vaginal suppository
Study Locations (7 sites)
Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge, New Jersey 07920 United States
Memorial Sloan Kettering Monmouth (Consent Only), Middletown, New Jersey 07748 United States
Memorial Sloan Kettering Bergen (Consent Only), Montvale, New Jersey 07645 United States
Memorial Sloan Kettering Cancer Center Suffolk-Commack (Consent Only), Commack, New York 11725 United States
Memorial Sloan Kettering Westchester (Consent Only), Harrison, New York 10604 United States
Memorial Sloan Kettering Cancer Center, New York, New York 10021 United States
Memorial Sloan Kettering Nassau (Consent Only), Uniondale, New York 11553 United States
Eligibility Criteria
Inclusion Criteria: * ≥18 years of age at the time of signing informed consent. * Stage 0-3 hormone-receptor positive breast cancer confirmed at MSKCC * Able to complete study questionnaires in English or Spanish * Breast cancer patients must have completed primary therapy (surgery, and/or chemotherapy, and/or radiation therapy) or currently on maintenance therapy * Currently on an aromatase inhibitor or tamoxifen or Selective Estrogen Receptor Modulators (SERM) * Currently have no clinical evidence of disease * Reporting being bothered by vaginal symptoms of estrogen deprivation (i.e., vaginal dryness, dyspareunia, or discomfort \[pain with intercourse or examination\]) * A total score of 4 or greater in VAS * Without history of other cancers (excluding non-melanoma skin cancer) * Must sign an informed consent indicating that the participant understands the purpose of, and procedures required for the study and is willing to participate in the study Exclusion Criteria: * Inability to provide informed consent * Vaginal bleeding of unknown etiology within 12 months of study entry * Currently taking hormone replacement therapy \[local or systemic\] (Patients must discontinue for 4 weeks in order to be eligible prior to study enrollment) * Existing use of external estrogens or nonhormonal moisturizers (Patients must discontinue for 4 weeks in order to be eligible prior to study enrollment) * No known allergies to any ingredients in 10mg HLA suppository
Conditions Venous Thromboembolism (VTE), Exercise T...
Phase NA
Enrollment 160
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Up to half of patients with pulmonary embolism (PE) suffer from impaired quality of life, reduced physical capacity, and symptoms like shortness of breath even three months after diagnosis, despite standard treatment with anticoagulation (blood thinners). The randomized RehabPE trial investigates whether an early, structured rehabilitation program with physical training and patient education can prevent such long-term effects. The study includes hospitalized patients with acute symptomatic PE who are at increased risk of impaired quality of life three months after diagnosis. After informed consent, patients are randomly assigned to one of two groups: one receives an early 6-8-week, center-based rehabilitation program; the other receives standard follow-up care without rehabilitation. The intervention group completes 16-18 outpatient sessions of endurance and strength training, along with two education sessions covering the condition, treatment, and symptom management. Over 180 days, changes in quality of life, physical exercise capacity, breathlessness, and psychological symptoms, and the time to return to work / usual daily activities will be monitored and compared between groups.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Other: Exercise-based rehabilitation program — Participants in the intervention group will receive a patient-tailored early (i.e., within 4 weeks of PE diagnosis) EBR program, comprising 16-18 sessions of supervised aerobic exercise and resistance/strength training at local outpatient rehabilitation centers, along with 2 PE-related educational sessions at 2 and 6 weeks of rehabilitation. Participants will receive comprehensive information on the purpose of EBR and each of its components, reassurance on its safety, and education on self-monitoring. Furthermore, physiotherapists will tailor the training based on specific capabilities, focusing on areas of weakness.

Primary Outcomes

  • Change in generic health-related quality of life (Physical Component Summary score; SF-36) (From baseline to day 90 after randomization)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-12-17
Completion: 2028-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Insel Gruppe AG, University Hospital Bern
Principal Investigators:
  • Tobias Tritschler, Prof. Dr. med., MSc (PRINCIPAL_INVESTIGATOR) - Inselspital, Universitätsspital Bern
Contact Information
Study Contact:
Tobias Tritschler, Prof. Dr. med., MSc
+41 (0)31 632 01 46
tobias.tritschler@insel.ch
Philipp Schütz, Prof. Dr. med.
+41 (0)62 838 95 24
philipp.schuetz@ksa.ch
Cantonal Hospital Aarau
Maria Wertli, Prof. Dr. med.
+41 (0)56 486 25 02
maria.wertli@ksb.ch
Cantonal Hospital Baden
Interventions
  • Other: Exercise-based rehabilitation program — Participants in the intervention group will receive a patient-tailored early (i.e., within 4 weeks of PE diagnosis) EBR program, comprising 16-18 sessions of supervised aerobic exercise and resistance/strength training at local outpatient rehabilitation centers, along with 2 PE-related educational sessions at 2 and 6 weeks of rehabilitation. Participants will receive comprehensive information on the purpose of EBR and each of its components, reassurance on its safety, and education on self-monitoring. Furthermore, physiotherapists will tailor the training based on specific capabilities, focusing on areas of weakness.
Study Locations (6 sites)
Cantonal Hospital Aarau, Aarau, Switzerland
Cantonal Hospital Baden, Baden, Switzerland
Inselspital, Bern University Hospital, Bern, 3010 Switzerland
Geneva University Hospitals, Geneva, Switzerland
Lausanne University Hospital, Lausanne, Switzerland
University Hospital Zürich, Zurich, Switzerland
Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 years 2. Hospitalization for objectively confirmed acute symptomatic PE, defined as intraluminal filling defect of a segmental or more proximal pulmonary artery on computed tomography pulmonary angiography (CTPA) or a high-probability ventilation-perfusion scintigraphy, and admission within the past 7 days 3. Increased risk for post-PE syndrome, defined as simplified Pulmonary Embolism Severity Index (sPESI) ≥1 point at the time of admission 4. Written informed consent Exclusion Criteria: 1. Contraindication to EBR (known unstable cardiac conditions like angina pectoris, severe valvular heart disease, or severe resting pulmonary hypertension) 2. Medical condition that clearly precludes participation in EBR (e.g., inability to walk, unstable joints, severe neurological impairment) 3. Recently completed (i.e., \<6 months), ongoing, or planned in- or outpatient EBR, or planned supervised outpatient physiotherapy for any indication 4. Planned hospitalization during follow-up (e.g., elective surgery or inpatient chemotherapy) 5. Contraindication to anticoagulation 6. Life expectancy \<1 year based on the treating physician's clinical judgement 7. Known pregnancy 8. Inability to speak German or French 9. Participation in another study that prohibits concurrent participation in RehabPE 10. Unable to provide informed consent (e.g., due to dementia) 11. Unwilling to provide informed consent 12. Prior enrollment in this study

SOS for Caregiver Wellbeing

NCT07136584
Recruiting
Conditions Mental Health, Depression and Burden in ...
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Parents and caregivers of children who have a chronic condition carry a large care burden and are at higher risk of having mental health symptoms. This study aims to see if completion of a mental health questionnaire by parents / caregivers at or before the child's paediatric appointment can help identify any symptoms of stress, anxiety or depression. Following the questionnaire, parents / caregivers will be provided with the results of the questionnaire along with an information resource sheet. This will include information on anxiety, stress and depression, as well as different agencies they can contact to get support. Parents / caregivers will be followed up at 3 and 6 months to see if they have any changes to mental health and quality of life, and whether they accessed any support services. Participants who did not complete the 3-month survey will be asked at the 6-month clinic visit to provide responses on an iPad to up to 5 questions selected from the 3-month survey. A text message will be sent prior to the visit to inform them. The primary aim for this trial is to see whether parents / caregivers find this process acceptable, and whether it can work in a busy hospital clinic.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Other: Screening, Outcomes and Referral Pathways — All participants complete baseline screening with follow up at 3 and 6 months. A key feature of the study is that a standardised information resource sheet (to community-based services) is provided to all caregivers, regardless of their screening scores. Primary outcomes focus on implementation feasibility and acceptability, while secondary outcomes examine service uptake and longitudinal measurement of caregiver wellbeing. This differs from existing research by providing resources universally rather than only to those scoring above clinical thresholds. Our longitudinal follow-up addresses an evidence gap identified in our systematic review - limited published data on downstream effects on actual service uptake and mental health outcomes over time. The services in the resource sheet also link to routine clinical care that doesn't require specialist support programs with dedicated funding.

Primary Outcomes

  • Acceptability of the overall SOS Model for caregivers (Day 7)
  • The proportion of eligible caregivers who provide informed consent and enrol in the trial (Through study completion, an average of 6 months)
  • The proportion of caregivers who report following up on a recommended service on the information resource sheet on the 3-month survey. (3 months)
  • The proportion of caregivers who report following up on a recommended service on the information resource sheet on the 6-month survey. (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-22
Completion: 2026-08
Eligibility
Age: Not reported
Sex: ALL
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Murdoch Childrens Research Institute
Collaborators: National Health and Medical Research Council, Australia, University of Melbourne, Royal Children's Hospital
Principal Investigators:
  • Nadia Coscini, BA, MBBS, MSc (PRINCIPAL_INVESTIGATOR) - Murdoch Children's Research Institute & University of Melbourne
Contact Information
Study Contact:
Nadia Coscini, BA, MBBS, MSc
+61 3 8341 6762
nadia.coscini@mcri.edu.au
Harriet Hiscock, MBBS, MD
+61 3 9345 6910
harriet.hiscock@rch.org.au
Interventions
  • Other: Screening, Outcomes and Referral Pathways — All participants complete baseline screening with follow up at 3 and 6 months. A key feature of the study is that a standardised information resource sheet (to community-based services) is provided to all caregivers, regardless of their screening scores. Primary outcomes focus on implementation feasibility and acceptability, while secondary outcomes examine service uptake and longitudinal measurement of caregiver wellbeing. This differs from existing research by providing resources universally rather than only to those scoring above clinical thresholds. Our longitudinal follow-up addresses an evidence gap identified in our systematic review - limited published data on downstream effects on actual service uptake and mental health outcomes over time. The services in the resource sheet also link to routine clinical care that doesn't require specialist support programs with dedicated funding.
Study Locations (1 sites)
Outpatient clinics - Royal Children's Hospital, Parkville, Victoria 3052 Australia
Eligibility Criteria
Inclusion Criteria: * must be a parent of a child \<18yo in an outpatient clinic at Royal Children's Hospital (in enrolled clinics either neuromuscular or diabetes) * able to complete a consent form in English without an interpreter Exclusion Criteria: * need for an interpreter to complete informed consent
Conditions Breast Cancer
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This fully, powered efficacy RCT, the MIND diet for Breast Cancer Cognition (MIND-BC), will evaluate the MIND diet in a rigorous, highly controlled academic cancer center. We will recruit breast cancer survivors reporting CRCI with a MIND diet score \< 8, based on a previously devised 14-item diet questionnaire designed to detect inadequate diet with respect to brain health (scores range from 0 to 14, with lower scores indicating a less adequate diet).14 Breast cancer survivors will have recently completed adjuvant treatment (i.e., 6 months to three years previously), to ensure that perceived cognitive impairment is likely chronic and due to cancer. To achieve maximal effect, the study consists of two 12-week phases 1) intervention phase, 2) maintenance phase.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: MIND Diet — a combination of the Mediterranean and DASH diets emphasizing consumption of high-nutrient, plant-based foods such as green leafy vegetables, nuts, berries, fish, and olive oil while limiting intake of foods high in saturated fat, pre-processed snacks, sugar, red and processed meat.
  • Other: Usual Diet — Check-in sessions for the usual diet arm will focus on general health (e.g., healthy hair, skin, eyesight). None of the topics will include dietary information for the usual diet arm.

Primary Outcomes

  • Efficacy of the MIND diet: Self-reported cognition (At 12 weeks and 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-09
Completion: 2030-03
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Sylvia Crowder (PRINCIPAL_INVESTIGATOR) - Moffitt Cancer Center
Contact Information
Study Contact:
Crystal Bryant
813-745-2168
Crystal.Bryant@moffitt.org
Sylvia Crowder, PhD
Moffitt Cancer Center
Heather Jim, PhD
Moffitt Cancer Center
Interventions
  • Other: MIND Diet — a combination of the Mediterranean and DASH diets emphasizing consumption of high-nutrient, plant-based foods such as green leafy vegetables, nuts, berries, fish, and olive oil while limiting intake of foods high in saturated fat, pre-processed snacks, sugar, red and processed meat.
  • Other: Usual Diet — Check-in sessions for the usual diet arm will focus on general health (e.g., healthy hair, skin, eyesight). None of the topics will include dietary information for the usual diet arm.
Study Locations (1 sites)
Moffitt Cancer Center, Tampa, Florida 33612 United States
Eligibility Criteria
Inclusion Criteria: * Previously diagnosed with stage I-III breast cancer. * Able to speak and read English. * Able to consume foods orally. * \>18 years of age. * Able to provide informed consent. * Have no documented or observable psychiatric or neurological disorder that would interfere with study participation (e.g., schizophrenia). * Report 'somewhat' to 'very much' cognitive impairment in the past week (i.e., a score ≥ 2 on a 0-4 scale) that they attribute to cancer or its treatment. * Report a MIND diet score \< 10 (range 0 to 14, higher score equates to higher diet quality). * Willing to consume the MIND diet. * Completed adjuvant treatment 6 months to three years previously. Exclusion Criteria: * Not meeting all of the inclusion criteria.
Conditions Diabetes Mellitus, Type 2, Physician-Pat...
Phase NA
Enrollment 250
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to test whether a communication strategy called "linguistic nudging" can help doctors and patients with type 2 diabetes make better treatment decisions together, and whether this improves patients' ability to manage their condition. What will happen in the study? - 250 adults with type 2 diabetes from Xiang'an Hospital (Xiamen) will be randomly assigned to one of two groups: Intervention group:Doctors will receive special training in "linguistic nudging" techniques to encourage shared decision-making. Patients will use a mobile app to record medication preferences, and doctors will adjust advice based on these preferences. Control group:Patients will receive standard diabetes care without these additional strategies. \- All participants will be followed for 6 months. What is the study aiming to find out? The main goal is to see if patients in the intervention group: Better follow medication plans Improve blood sugar monitoring Have better blood sugar control Feel more satisfied with doctor-patient communication Why is this important? Good self-management is key to controlling diabetes, but many patients struggle with it. Effective communication during shared decision-making may empower patients to manage their condition day-to-day with greater confidence. Patient safety and rights: Participation is completely voluntary All personal information will be kept strictly confidential Medical support will be provided if any health problems occur during the study Participants may withdraw at any time This research has been approved by the Ethics Committee of Xiang'an Hospital (Approval date: October 2025).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: Linguistic Nudging Training — Physicians receive 4-hour communication training to optimize shared decision-making using behavioral nudging techniques
  • Device: Medication Preference App — Patients use WeChat-based mini-program to record daily medication preferences and concerns
  • Other: Standard Diabetes Care — Routine follow-up visits, HbA1c monitoring, and basic health education per hospital protocol

Primary Outcomes

  • Change in Glycated Hemoglobin (HbA1c) Level (Baseline and Month 6)
  • Diabetes Self-Management Capacity Scale Score (Baseline, Month 3, Month 6)
  • Shared Decision Making Questionnaire (SDM-Q-9) Score (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-01
Completion: 2026-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 250 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yunxuan Li
Contact Information
Study Contact:
Wei WANG, M.D.
+8613939809540
wwei19742007@hotmail.com
Yunxuan Li, Master Candidate
+8613939809540
yunxuanli@stu.xmu.edu.cn
Yunxuan Li, Student
+8613939809540
1737178679@qq.com
Xiang'an Hospital Affiliated to Xiamen University
Interventions
  • Behavioral: Linguistic Nudging Training — Physicians receive 4-hour communication training to optimize shared decision-making using behavioral nudging techniques
  • Device: Medication Preference App — Patients use WeChat-based mini-program to record daily medication preferences and concerns
  • Other: Standard Diabetes Care — Routine follow-up visits, HbA1c monitoring, and basic health education per hospital protocol
Study Locations (1 sites)
Xiang'an Hospital Affiliated to Xiamen University, Xiamen, Fujian 0592361101 China
Eligibility Criteria
Inclusion Criteria: * Confirmed diagnosis of type 2 diabetes * Age ≥ 18 years * Normal cognitive function (assessed by Mini-Cog score ≥ 3) * Basic smartphone operation ability (can independently use WeChat) * Willing to participate and sign informed consent Exclusion Criteria: * Severe acute complications (e.g., ketoacidosis, hyperosmolar coma) * Documented cognitive impairment (dementia, Alzheimer's, etc.) * Currently participating in other clinical trials * Life expectancy \< 6 months * Pregnancy or lactation
Conditions Pulmonary Arterial Hypertension, Pulmona...
Phase Not Applicable
Enrollment 183
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Pulmonary arterial hypertension (PAH) is a rare, progressive, and potentially life-threatening disease characterized by pulmonary vascular remodeling, increased pulmonary vascular resistance, and right ventricular dysfunction. The endothelin pathway plays a central role in its pathophysiology and is targeted by endothelin receptor antagonists (ERAs), including ambrisentan and bosentan. Ambrisentan is a selective ETA receptor antagonist, whereas bosentan blocks both ETA and ETB receptors. Although transitions between ERAs occur in clinical practice, evidence regarding the clinical impact of switching from ambrisentan to bosentan remains limited. ACTION is a retrospective, observational, single-center cohort study evaluating adult patients with pulmonary arterial hypertension (World Health Organization Group 1) and/or chronic thromboembolic pulmonary hypertension (World Health Organization Group 4) confirmed by right heart catheterization. Patients who switched from ambrisentan to bosentan because of a national ambrisentan shortage will be compared with clinically similar patients who remained on ambrisentan. Clinical, functional, and laboratory data recorded at baseline and at 3 to 6 months of follow-up will be assessed. The primary outcome is the proportion of patients with worsening risk stratification after switching from ambrisentan to bosentan compared with patients who continued ambrisentan. Risk will be evaluated using the COMPERA 2.0 and REVEAL Lite 2 assessment tools. Secondary outcomes include changes in World Health Organization/New York Heart Association functional class, 6-minute walk distance, BNP levels, individual risk-assessment components, hepatic enzymes, hemoglobin levels, and clinically relevant events such as hospitalization, emergency department visits, initiation of supplemental oxygen, and right heart failure decompensation.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Interventions / Regimen

  • Other: Switch from Ambrisentan to Bosentan — This intervention refers to a therapeutic switch from ambrisentan (10 mg once daily) to bosentan (125 mg twice daily) in adult patients with pulmonary arterial hypertension (PAH), performed as part of routine clinical care. The switch was not assigned by the investigators but was made based on clinical indications prior to study enrollment. Patients are followed prospectively for up to 6 months to assess changes in risk stratification, functional status, laboratory parameters, and safety outcomes.
  • Drug: Maintenance of Ambrisentan Therapy — Continued treatment with ambrisentan 10 mg once daily without transition to bosentan, as part of routine clinical care. Treatment was not assigned by the investigators. Clinical, functional, laboratory, and safety outcomes are assessed over a 3- to 6-month period.

Primary Outcomes

  • Change in risk category according to used scores (From 3 to 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-08-20
Completion: 2026-12-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 183 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Sao Paulo General Hospital
Contact Information
Study Contact:
Caio Fernandes, Principal Investigator
PhD
caio.cesar@hc.fm.usp.br
Caio Fernandes, PhD
+55 11 2661-1548
caio.cesar@hc.fm.usp.br
InCor - FMUSP
Interventions
  • Other: Switch from Ambrisentan to Bosentan — This intervention refers to a therapeutic switch from ambrisentan (10 mg once daily) to bosentan (125 mg twice daily) in adult patients with pulmonary arterial hypertension (PAH), performed as part of routine clinical care. The switch was not assigned by the investigators but was made based on clinical indications prior to study enrollment. Patients are followed prospectively for up to 6 months to assess changes in risk stratification, functional status, laboratory parameters, and safety outcomes.
  • Drug: Maintenance of Ambrisentan Therapy — Continued treatment with ambrisentan 10 mg once daily without transition to bosentan, as part of routine clinical care. Treatment was not assigned by the investigators. Clinical, functional, laboratory, and safety outcomes are assessed over a 3- to 6-month period.
Study Locations (1 sites)
InCor - FMUSP, São Paulo, São Paulo Brazil
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Confirmed diagnosis of pulmonary arterial hypertension (PAH) by right heart catheterization * Documented therapeutic switch from ambrisentan (10 mg once daily) to bosentan (125 mg twice daily) within the previous 6 months for the switch group * Treatment with ambrisentan for at least 6 months without switching to bosentan for the maintenance group Exclusion Criteria: * History of severe hepatic impairment * Incomplete clinical or laboratory records that prevent risk score calculation * Inability to attend clinical follow-up between 3 and 6 months after medication switch
Conditions Metastatic Breast Cancer, HER2 + Breast ...
Phase PHASE1
Enrollment 21
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a FiH phase 1, open-label, two-stage, randomized trial to assess the safety, tolerability, and biodistribution of \[177Lu\]Lu-ABY-271 in subjects with HER2 positive metastatic breast cancer.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: [177Lu]Lu-ABY-271 — A single infusion of \[177Lu\]Lu-ABY-271

Primary Outcomes

  • Treatment emergent adverse events (From baseline to the end-of-trial visit, for part A Day 29 and for part B Day 43)
  • Dose Limiting Toxicities (From baseline to the end-of-trial visit, for part A Day 29 and for part B Day 43)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-10-06
Completion: 2028-06-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 21 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Affibody
Contact Information
Study Contact:
Affibody AB
46859883800
ABY-271-101@affibody.se
Interventions
  • Drug: [177Lu]Lu-ABY-271 — A single infusion of \[177Lu\]Lu-ABY-271
Study Locations (3 sites)
Sahlgrenska University Hospital, Gothenburg, S-413 45 Sweden
Karolinska University Hospital, Stockholm, SE-17164 Sweden
Akademiska Sjukhuset, Uppsala, SE-751 85 Sweden
Eligibility Criteria
Inclusion Criteria: * Subject has unresectable locally advanced or metastatic breast cancer * Subject with histologically or cytologically confirmed carcinoma with documented HER2 overexpression (biopsy not older than 2 years): immunohistochemistry (IHC) score 3+; OR 2+ and fluorescence in situ hybridization (ISH) positive * At least one known tumor lesion ≥ 15 mm * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 Part A only \- Subject is in treatment, or planned to start a new line of standard systemic anti-tumor therapy Part B only * Subject has progressive disease, documented radiologically in the last three months * Subject has received at least 3 lines of standard systemic anti-tumor therapy in the palliative setting * Subject has received last dose of previous line of systemic anti-tumor therapy, and has no ongoing treatment related toxicities \> grade 1 (except alopecia) prior to planned first dose of \[177Lu\]Lu-ABY-271 Exclusion Criteria: * Active brain metastases * Administration of another IMP within 5 half-lives (for experimental biologics: 6 months or 5 half-lives, whichever is longer) of the planned first dose of \[177Lu\]Lu-ABY-271 * Exposure to any anti-tumor therapy since the last documented progression, including any radiotherapy within 7 days prior to the planned first dose of \[177Lu\]Lu-ABY-271
Conditions Depressive Symptoms, Anxiety Symptoms, C...
Phase NA
Enrollment 110
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to evaluate a novel cultural strengths parenting program - the Video-feedback Intervention to Promote Racial-Ethnic Socialization CompEtency (VIP-RACE) - which seeks to support Latine parents' motivation to engage in racial-ethnic socialization (RES) and strengthen their RES competency (improved skills and confidence, decreased stress). In the preliminary phases of this project, we iteratively refined the VIP-RACE program in partnership with advisory boards of youth, parents, and providers. The refined intervention will now be tested with five parents of 10-14-year-old Latine youth to identify gaps in the curriculum and obstacles to implementation that can be addressed prior to a larger pilot. The investigators will then conduct a proof-of-concept single-arm trial with Latine families to assess the feasibility, acceptability, and preliminary efficacy of VIP-RACE. The investigators hypothesize that VIP-RACE will be shown to be feasible and acceptable to families. The investigators also predict that bolstering parents' RES motivation and competency will result in increased frequency and quality of these conversations between parents and youth which, in turn, are expected to strengthen youth racial-ethnic identity and coping and have cascading effects on mental and behavioral health.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Video-feedback Intervention to Promote Racial-Ethnic Socialization CompEtency (VIP-RACE) — VIP-RACE is a brief, strengths-based, video-feedback intervention that targets parental racial-ethnic socialization (RES) motivation and competency in parents of 10-to-14-year-old Latino/a/x/e youth. Intervention sessions include: (1) Youth and parent assessment including videotaped parent-adolescent RES conversations; (2) Parent interview; and (3) Video feedback session during which parents and RES coaches review clips from the RES interaction tasks. Video feedback highlights parents' RES strengths and when sensitively applied, encourages parents to examine missed opportunities for engaging in RES. RES coaches emphasize that through the provision of cultural socialization and preparation for bias messages, parents can help protect their children from the damaging effects of discrimination and support positive racial-ethnic identity development. Parents develop a personalized action plan with goals and have the opportunity to receive up to 3-5 follow-up sessions to strengthen RES skill

Primary Outcomes

  • Feasibility (Quantitative) (Immediately after the intervention)
  • Acceptability (Quantitative) (Immediately after the intervention)
  • Feasibility and Acceptability (Qualitative) (Immediately after the intervention)
  • Feasibility (Attendance tracking) (Through study completion, an average of 9 weeks)
  • Change in Parental Racial-Ethnic Socialization (RES) Motivation (Baseline, immediately after the intervention, and 1-month follow-up)
  • Change in Parental RES Competency (Baseline, immediately after the intervention, and 1-month follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-12
Completion: 2027-03-31
Eligibility
Age: 10 Years and older
Sex: ALL
Volunteers: true
Enrollment: 110 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Penn State University
Collaborators: National Institute on Minority Health and Health Disparities (NIMHD)
Principal Investigators:
  • Principal Investigator (PRINCIPAL_INVESTIGATOR) - The Pennsylvania State University
Contact Information
Study Contact:
Principal Investigator
626-205-5563
cag6443@psu.edu
Project Coordinator
240-374-8559
bvg5454@psu.edu
Principal Investigator
626-205-5563
cag6443@psu.edu
Parents and Children Together (PACT) Lab Space
Interventions
  • Behavioral: Video-feedback Intervention to Promote Racial-Ethnic Socialization CompEtency (VIP-RACE) — VIP-RACE is a brief, strengths-based, video-feedback intervention that targets parental racial-ethnic socialization (RES) motivation and competency in parents of 10-to-14-year-old Latino/a/x/e youth. Intervention sessions include: (1) Youth and parent assessment including videotaped parent-adolescent RES conversations; (2) Parent interview; and (3) Video feedback session during which parents and RES coaches review clips from the RES interaction tasks. Video feedback highlights parents' RES strengths and when sensitively applied, encourages parents to examine missed opportunities for engaging in RES. RES coaches emphasize that through the provision of cultural socialization and preparation for bias messages, parents can help protect their children from the damaging effects of discrimination and support positive racial-ethnic identity development. Parents develop a personalized action plan with goals and have the opportunity to receive up to 3-5 follow-up sessions to strengthen RES skill
Study Locations (1 sites)
Parents and Children Together (PACT) Lab Space, Harrisburg, Pennsylvania 17102 United States
Eligibility Criteria
Inclusion Criteria: * Adolescent is 10-to-14 years old (inclusive) * Adolescent and parent are Latino/a/x/e or Hispanic * Parent and youth have the capacity to provide consent/assent * One parent is willing to participate * Families must be willing to be video or audio recorded for the parent-child interaction task * Youth and parent(s) must be willing to participate as dyads. * Primary language of parent and adolescent is English and/or Spanish Exclusion Criteria: * Parent or adolescent has an intellectual disability, autism spectrum disorder, or other disorder that may limit ability to complete study (surveys and interviews require sustained attention, mental processing, and comprehension). * Adolescent is not 10-to-14 years old * Adolescent and/or parent are not Latino/a/x/e or Hispanic * Primary language of parent and/or adolescent is not English and/or Spanish * Youth and parent(s) are not willing to participate as dyads * Family participated in Phase 1 of the study
Conditions Anatomic Stage III Breast Cancer AJCC v8...
Phase PHASE1
Enrollment 36
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This phase I trial tests the safety, side effects, and best dose of pidnarulex in combination with trastuzumab deruxtecan in treating patients with breast cancer and other solid tumors that express varying levels of a protein called HER2 and that has spread from where it first started (primary site) to other places in the body (metastatic), that cannot be removed by surgery (unresectable), or that has spread to nearby tissue or lymph nodes (locally advanced). Pidnarulex is an enzyme inhibitor that causes cell death and prevents tumor cell growth. Trastuzumab deruxtecan is in a class of medications called antibody-drug conjugates. It is composed of a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive tumor cells in a targeted way and delivers deruxtecan to kill them. Giving pidnarulex in combination with trastuzumab deruxtecan may be safe, tolerable and/or effective in treating patients with metastatic, unresectable, or locally advanced HER2-expressing breast cancer or other solid tumors.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Biopsy Procedure — Undergo biopsy
  • Procedure: Biospecimen Collection — Undergo collection of blood samples
  • Procedure: Echocardiography Test — Undergo ECHO
  • Procedure: Multigated Acquisition Scan — Undergo MUGA
  • Drug: Pidnarulex — Given IV
  • Procedure: Radiologic Imaging Procedure — Undergo radiologic imaging
  • Biological: Trastuzumab Deruxtecan — Given IV

Primary Outcomes

  • Maximum tolerated dose (dose escalation phase) (Up to completion of dose-escalation)
  • Incidence of adverse events with drug combination at the recommended phase 2 dose (dose expansion phase) (Up to 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-10-05
Completion: 2028-01-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 36 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Cancer Institute (NCI)
Principal Investigators:
  • Filipa Lynce (PRINCIPAL_INVESTIGATOR) - Dana-Farber - Harvard Cancer Center LAO
Contact Information
Study Contact:
Site Public Contact
877-442-3324
Dana-Farber Cancer Institute
Filipa Lynce
Dana-Farber Cancer Institute
Site Public Contact
800-600-3606
info@siteman.wustl.edu
Washington University School of Medicine
Interventions
  • Procedure: Biopsy Procedure — Undergo biopsy
  • Procedure: Biospecimen Collection — Undergo collection of blood samples
  • Procedure: Echocardiography Test — Undergo ECHO
  • Procedure: Multigated Acquisition Scan — Undergo MUGA
  • Drug: Pidnarulex — Given IV
Study Locations (2 sites)
Dana-Farber Cancer Institute, Boston, Massachusetts 02215 United States
Washington University School of Medicine, St Louis, Missouri 63110 United States
Eligibility Criteria
Inclusion Criteria: * DOSE ESCALATION PHASE ONLY: Patients must have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective * DOSE EXPANSION PHASE ONLY: Participants must have histologically or cytologically confirmed invasive breast cancer, with either locally advanced or metastatic disease * Age ≥ 18 years. Because no dosing or adverse event data are currently available on the use of CX-5461 (pidnarulex) in combination with T-DXd in patients \< 18 years of age, children are excluded from this study * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%) * Absolute neutrophil count (ANC) ≥ 1,500/mcL * No administration of granulocyte colony-stimulating factor (G-CSF) is allowed within 1 week prior to screening assessment * Platelets ≥ 100,000/mcL * No transfusions with red blood cells or platelets are allowed within 1 week prior to screening assessment * Total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN) (or ≤ 2 × institutional ULN in patients with documented Gilbert's syndrome) * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) ≤ 3 × institutional ULN (or ≤ 5 × ULN in patients with liver metastases) * International normalized ratio (INR)/prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN * Glomerular filtration rate (GFR) ≥ 60 mL/min/1.73 m\^2 (using the Cockcroft-Gault equation for participants with creatinine levels above institutional ULN) * Patients must have had at least one prior line of cytotoxic chemotherapy. Patients can have received an unlimited number of additional lines of chemotherapy, targeted therapy, biologic therapy, or hormonal therapy. Patients must not have progressed on a prior anthracycline in the metastatic setting. Receipt of anthracycline in the (neo)adjuvant setting is allowed, provided that disease recurrence occurred later than 6 months after the completion of treatment * Prior poly (ADP-ribose) polymerase (PARP) inhibition is allowed * No specific germline mutation is required * DOSE ESCALATION PHASE ONLY: * HER2-positive (IHC 3+) solid cancers, * HR+ HER2 positive/low/ultralow breast cancer or triple negative breast cancer (TNBC) HER2-low breast cancer, with HER2 positive defined by the current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines, * HER2-low, with HER2-low defined as IHC 2+/in situ hybridization (ISH)-, IHC 1+/ISH-, or IHC 1+/ISH untested * DOSE EXPANSION PHASE ONLY: * Either the primary invasive tumor and/or the metastasis must be: * HER2-low, with HER2-low defined as IHC 2+/ISH-, IHC 1+/ISH-, or IHC 1+/ISH untested. Any estrogen receptor (ER) and progesterone receptor (PR) expression is permitted but must be known, or * HR+ HER2-ultralow defined as IHC 0 with membrane staining * Participants must have at least one lesion that is not within a previously radiated field that is measurable per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1. Bone lesions are not considered measurable by definition. Biopsy of the lesion that will be used for disease evaluation (measurable disease) is not allowed in the dose expansion portion of this study * Peripheral neuropathy grade ≤ 1 * Patients must have left ventricular ejection fraction (LVEF) ≥ 50% by either an echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan within 28 days before randomization/enrollment * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load * Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression * Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class II or better * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * The effects of CX-5461 (pidnarulex) and T-DXd on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) 14 days prior to study entry and for the duration of study participation and for at least 7 months (women of childbearing potential \[WOCBP\] only) after the last dose of study drug. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Women should not breastfeed while taking CX-5461 (pidnarulex) and T-DXd and for 7 months after cessation of treatment. Men treated or enrolled on this protocol must also agree to use adequate contraception 14 days prior to the study, for the duration of study participation, and 6 months after completion of CX-5461 (pidnarulex) and T-DXd administration * Women of non-child-bearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases, a blood sample with simultaneous follicle-stimulating hormone \[FSH\] \> 40 mIU/mL and estradiol \< 40 pg/mL \[\< 147 pmol/L\] is confirmatory) or on ovarian suppression are eligible. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods outlined for women of child-bearing potential if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method * Male patients must not freeze or donate sperm starting at screening and throughout the study period, and at least 6 months after the final study drug administration. Preservation of sperm should be considered prior to enrollment in this study * Female patients must not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and for at least 7 months after the final study drug administration * Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives (LAR) may sign and give informed consent on behalf of study participants * Patients who have had chest radiation therapy within 4 weeks (2 weeks for palliative stereotactic radiation therapy). These patients will be excluded because T-DXd is known to i
Conditions Breast Cancer
Phase NA
Enrollment 132
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this prospective, single-arm, phase II, non-randomized trial is to evaluate an hypofractionation schedule with high dose simultaneous integrated tumor bed boost in early breast cancer patients. The main question\[s\] it aims to answer are: * evaluate the rate of all grades of radiation-induced fibrosis at 4 years. * evaluate poor/fair cosmesis rate Participants will be treated with hypofractionated radiotherapy (RT) to whole breast with a dose of 40.05 Gy in 15 fractions (2.67 Gy/die) and a concomitant tumor bed dose of 52.5 Gy (3.5 gy/die)

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: hypofractionated radiotherapy with tumor bed boost — hypofractionated radiotherapy with concomitant/simultaneous tumor bed boost

Primary Outcomes

  • Breast fibrosis (baseline, each year up to 4 years after radiotherapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2020-03-12
Completion: 2030-03
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 132 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondazione Policlinico Universitario Campus Bio-Medico
Contact Information
Study Contact:
Edy Ippolito, Prof
+3906225418081
e.ippolito@unicampus.it
Sara Ramella, Prof
Università Campus Biomedico
Interventions
  • Radiation: hypofractionated radiotherapy with tumor bed boost — hypofractionated radiotherapy with concomitant/simultaneous tumor bed boost
Study Locations (1 sites)
Università Campus Biomedico, Roma, Italy
Eligibility Criteria
Inclusion Criteria: * histologically proven breast cancer who have undergone conservative surgery * at least 3 inserted clips * age: from 18 years old to 50 years * at least one of the following risk factors: N1 disease, LVI, extensive intraductal component (\>25%), close margins (\<4 mm), non-hormone-sensitive disease, grading 3 * ECOG performance status \< 2 * adequate bone marrow (haemoglobin concentration \> 8 g/dl, white blood cell count \> 3000/mm3, platelet count \> 75000). Exclusion Criteria: * Previous chest radiation treatment * Bilateral breast cancer * Neoadjuvant chemotherapy * BMI \> 35 * Collagen diseases * Pregnancy or breastfeeding
Conditions Asthma Childhood, Asthma Attack, Remote ...
Phase Not Applicable
Enrollment 900
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The objective of this study is to determine whether healthcare data and remotely collected patient data can accurately predict asthma attacks in children and young people aged 5-17 years. The main outcome is: when using this new system, is there a reduction in asthma attacks compared with a historic average. The whole population of children and young people with asthma will have routine healthcare data monitored, with a subset of people with high risk asthma asked to participate in a more detail study involving remotely monitored data.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Number of asthma attacks (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-11-20
Completion: 2027-03-01
Eligibility
Age: 5 Years and older
Sex: ALL
Volunteers: false
Enrollment: 900 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Edinburgh
Contact Information
Study Contact:
kenneth a macleod, MbChB, PhD
+441313120453
Kenneth.Macleod3@nhs.scot
Kenneth Macleod
Kenneth.Macleod3@nhs.scot
NHS Lothian
Interventions
N/A
Study Locations (1 sites)
NHS Lothian, Edinburgh, United Kingdom
Eligibility Criteria
Inclusion Criteria: * Children and Young People with a diagnosis of asthma (coded as asthma or suspected asthma) or a prescription of inhaled corticosteroid in the prior 2 years. Exclusion Criteria: * Alternative non-asthma diagnosis that would require inhaled steroid * cystic fibrosis * bronchiectasis * primary ciliary dyskinaesia
Conditions Breast Cancer Survivor, Obesity, Overwei...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this intervention is to investigate whether transcranial Direct Current Stimulation (tDCS) can alleviate Cancer-Related Cognitive Impairment (CRCI) in breast cancer survivors, as measured by changes in brain structures and cognitive performance. To assess the efficacy of tDCS, the investigators will compare outcomes between participants receiving active stimulation and those receiving sham stimulation (a placebo condition where participants believe they are receiving stimulation, but are not). Participants will: * Undergo a baseline MRI session * Receive either active or sham tDCS for six weeks * Undergo a follow-up MRI session * Complete cognitive tests and respond to psychosocial questionnaires before, during, and after the tDCS intervention

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Quadruple

Interventions / Regimen

  • Device: active tDCS — The anodal electrode will be placed over the left DLPFC (F3), and the cathodal electrode will be placed over the right supraorbital area (FP2). The current will be gradually ramped up to 2mA over 30 seconds, held constant at 2mA for 29 minutes, and then gradually ramped down to 0mA over the final 30 seconds.
  • Device: sham tDCS — The anodal electrode will be placed over the left DLPFC (F3), and the cathodal electrode will be placed over the right supraorbital area (FP2). The current will be initially ramped up to 2mA over 30 seconds and immediately ramped back down to 0mA.

Primary Outcomes

  • Attention at post-intervention (From baseline to the end of the intervention at 6 weeks)
  • Short-term episodic memory at post-intervention (From baseline to the end of the intervention at 6 weeks)
  • Processing speed at post-intervention (From baseline to the end of the intervention at 6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-01
Completion: 2027-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Helsinki
Contact Information
Study Contact:
Manon Chédeville, Doctoral Researcher
+358 50 326 4109
manon.chedeville@helsinki.fi
Manon Chédeville, Doctoral Researcher
+358 50 326 4109
manon.chedeville@helsinki.fi
Department of Psychology, Faculty of Medicine, University of Helsinki
Professor Horstmann
Department of Psychology, Faculty of Medicine, University of Helsinki
Interventions
  • Device: active tDCS — The anodal electrode will be placed over the left DLPFC (F3), and the cathodal electrode will be placed over the right supraorbital area (FP2). The current will be gradually ramped up to 2mA over 30 seconds, held constant at 2mA for 29 minutes, and then gradually ramped down to 0mA over the final 30 seconds.
  • Device: sham tDCS — The anodal electrode will be placed over the left DLPFC (F3), and the cathodal electrode will be placed over the right supraorbital area (FP2). The current will be initially ramped up to 2mA over 30 seconds and immediately ramped back down to 0mA.
Study Locations (1 sites)
Department of Psychology, Faculty of Medicine, University of Helsinki, Helsinki, Uusimaa 00200 Finland
Eligibility Criteria
Inclusion Criteria: * Female * Over 18 years old * Diagnosed with primary adult-onset breast cancer within the last 5 years * Completed all active cancer treatments at least 3 months prior to study participation * Capable of fulfilling study requirements, including having internet access. * Fluent in either Finnish or English * Have normal or corrected vision and hearing * Right-handed (based on the Edinburgh Handedness Inventory score; Oldfield, 1971) Exclusion Criteria: * Have received primary cancer treatment (chemotherapy, radiotherapy, immunotherapy, or surgery) within the last 3 months * Have a history of childhood-onset cancer * Present with acute eczema on the scalp * Diagnosed with dementia, Alzheimer's disease, multiple sclerosis, or - Parkinson's disease * Have experienced unconsciousness for more than five minutes due to a head/brain injury within the last 10 years * Have a history of stroke or transient ischemic attack * Suffer from claustrophobia * Are pregnant or breastfeeding * Have any of the following medical implants or devices: cardiac implantable electronic devices, metallic intraocular foreign bodies, neurostimulation systems, cochlear/ear implants, drug infusion pumps, catheters with metal components, metallic fragments (e.g., bullets), cerebral aneurysm clips, magnetic dental implants, tissue expanders, artificial limbs, non-removable piercings, or face tattoos. * Weight exceeding 250 kg (the MRI table weight limit) or they are unable to fit within the 70 cm diameter bore of the MRI machine